Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRI + cetuximab modulation by RAS mutation load in RAS-mutated mCRC
DRKS00023034Phase 2Completed
- Sponsor
- TheraOp gGmbH Hanno Härtlein Winchesterstr. 3
- Start
- Sep 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab, irinotecan, folinic acid and fluorouracil in colorectal cancer (CRC), rectosigmoid cancer and metastatic colorectal adenocarcinoma (mCRC), sponsored by TheraOp gGmbH Hanno Härtlein Winchesterstr. 3. Started Sep 2020; status: completed.
02
Drugs
cetuximabirinotecanfolinic acidfluorouracil
03
Conditions
colorectal cancer (CRC)rectosigmoid cancermetastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on DRKS00023034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00023034.